{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:48:34Z","timestamp":1792050514487,"version":"4.4.0"},"posted":{"date-parts":[[2025,11,23]]},"group-title":"Oncology","reference-count":25,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T00:00:00Z","timestamp":1763856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,11,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Real-world data suggest that SARS-CoV-2 mRNA vaccines, administered within 100 days of immune checkpoint inhibitor (ICI) treatment (\u201cperi-ICI vaccination\u201d), may improve ICI effectiveness, potentially through synergistic immune priming. Although peri-ICI vaccination was associated with longer survival when we applied a previous framework to our independent dataset, additional patterns emerged. Peri-ICI vaccination benefit diminished after 2021, a pattern confirmed in re-analysis of a published cohort. Benefit extended to patients treated with non-ICI antineoplastics. Benefit also dissipated in landmarked analyses restricted to periods of vaccine eligibility. Finally, progression-free survival in time periods with high vaccine uptake was not longer than in periods without vaccination. These analyses suggest peri-ICI vaccination\u2019s observed association with survival largely reflects selection bias in which patients with better prognosis were more likely to receive SARS-CoV-2 vaccines.<\/jats:p>","DOI":"10.1101\/2025.11.21.25340753","type":"posted-content","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T04:40:11Z","timestamp":1763959211000},"source":"Crossref","is-referenced-by-count":4,"title":["Deconvolving SARS-CoV-2 mRNA vaccine impact on immunotherapy-related survival in a pandemic"],"prefix":"10.64898","author":[{"given":"Justin","family":"Jee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Lavery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Minn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7918-5164","authenticated-orcid":false,"given":"Michael","family":"Glickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine S.","family":"Panageas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Sawyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2025112506450595000_2025.11.21.25340753v1.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09655-y"},{"key":"2025112506450595000_2025.11.21.25340753v1.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01163-9"},{"key":"2025112506450595000_2025.11.21.25340753v1.3","first-page":"1437","article-title":"Sensitization of tumours to immunotherapy by boosting early type-I interferon responses enables epitope spreading. Nat","volume":"9","year":"2025","journal-title":"Biomed. Eng"},{"key":"2025112506450595000_2025.11.21.25340753v1.4","first-page":"565","article-title":"The impact of the COVID-19 pandemic on cancer care. Nat","volume":"1","year":"2020","journal-title":"Cancer"},{"key":"2025112506450595000_2025.11.21.25340753v1.5","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1126\/science.adw4964","article-title":"Collateral effects of COVID-19 pandemic control on the US infectious disease landscape","volume":"390","year":"2025","journal-title":"Science (80-.)"},{"key":"2025112506450595000_2025.11.21.25340753v1.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2510226"},{"key":"2025112506450595000_2025.11.21.25340753v1.7","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1200\/JCO.20.01307","article-title":"Chemotherapy and COVID-19 Outcomes in Patients With Cancer","volume":"38","year":"2020","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol"},{"key":"2025112506450595000_2025.11.21.25340753v1.8","first-page":"e2400034","article-title":"Differential survival among patients with cancer by COVID-19 vaccination status: an analysis of the ASCO COVID-19 registry","volume":"1","year":"2024","journal-title":"JCO Oncol. Adv"},{"key":"2025112506450595000_2025.11.21.25340753v1.9","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1001\/jamaoncol.2025.2020","article-title":"COVID-19 Vaccine Booster Uptake and Effectiveness Among US Adults With Cancer","volume":"11","year":"2025","journal-title":"JAMA Oncol"},{"key":"2025112506450595000_2025.11.21.25340753v1.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08167-5"},{"key":"2025112506450595000_2025.11.21.25340753v1.11","first-page":"e2243127","article-title":"Return on Investment of the COVID-19 Vaccination Campaign in New York City. JAMA Netw","volume":"5","year":"2022","journal-title":"Open"},{"key":"2025112506450595000_2025.11.21.25340753v1.12","doi-asserted-by":"crossref","first-page":"2196436","DOI":"10.1080\/07853890.2023.2196436","article-title":"Exclusive and dual influenza and COVID-19 vaccination among U.S. adults and adolescents in 2021","volume":"55","year":"2023","journal-title":"Ann. Med"},{"key":"2025112506450595000_2025.11.21.25340753v1.13","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(96)00075-X"},{"key":"2025112506450595000_2025.11.21.25340753v1.14","unstructured":"Triesman, R. New York lifts indoor mask mandate, with California and N.J. mandates also set to end. NPR (2022)."},{"key":"2025112506450595000_2025.11.21.25340753v1.15","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2103695"},{"key":"2025112506450595000_2025.11.21.25340753v1.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577"},{"key":"2025112506450595000_2025.11.21.25340753v1.17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.11151"},{"key":"2025112506450595000_2025.11.21.25340753v1.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00372-2"},{"key":"2025112506450595000_2025.11.21.25340753v1.19","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200802-282OC"},{"key":"2025112506450595000_2025.11.21.25340753v1.20","doi-asserted-by":"crossref","unstructured":"Hassel, J. , et al. LBA53 - IO102-IO103 cancer vaccine plus pembrolizumab for first line (1L) advanced melanoma: Primary phase III results (IOB-013\/KN-D18). in ESMO Congress (2025).","DOI":"10.1016\/j.annonc.2025.09.065"},{"key":"2025112506450595000_2025.11.21.25340753v1.21","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41573-025-01211-7","article-title":"The gut microbiome as a target in cancer immunotherapy: opportunities and challenges for drug development","volume":"24","year":"2025","journal-title":"Nat. Rev. Drug Discov"},{"key":"2025112506450595000_2025.11.21.25340753v1.22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12967-023-04110-w","article-title":"Spontaneous cancer remission after COVID-19: insights from the pandemic and their relevance for cancer treatment","volume":"21","year":"2023","journal-title":"J. Transl. Med"},{"key":"2025112506450595000_2025.11.21.25340753v1.23","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.ccell.2025.05.002","article-title":"Microbial cancer immunotherapy reprograms hematopoiesis to enhance myeloid-driven anti-tumor immunity","volume":"43","year":"2025","journal-title":"Cancer Cell"},{"key":"2025112506450595000_2025.11.21.25340753v1.24","doi-asserted-by":"crossref","unstructured":"Costin D , Meshad M, J. R. TeLuRide-005: phase 2 study of EIK1001, a toll-like receptor 7\/8 co-agonist with pembrolizumab + chemotherapy as first-line therapy in stage 4 non-small cell lung cancer. in ESMO Congress (2025).","DOI":"10.1016\/j.annonc.2025.08.2474"},{"key":"2025112506450595000_2025.11.21.25340753v1.25","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaoncol.2021.5153","article-title":"Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies","volume":"8","year":"2022","journal-title":"JAMA Oncol"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.11.21.25340753","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:51:54Z","timestamp":1768510314000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.11.21.25340753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,23]]},"references-count":25,"URL":"https:\/\/doi.org\/10.1101\/2025.11.21.25340753","relation":{},"subject":[],"published":{"date-parts":[[2025,11,23]]},"subtype":"preprint"}}